Whale watchers encounter 2 great white sharks off North Shore
Whale watchers got a big surprise when they encountered two great white sharks in the water off the North Shore of Massachusetts on Wednesday.
7 Seas Whale Watch said in a Facebook post that its vessel was heading out to sea when a naturalist onboard spotted a fin in the water about 10 miles north of Gloucester.
'We could tell it was either a great white or a short-finned mako - both of which are rare - but needed a better look to positively identify the animal,' 7 Seas wrote in the post. 'When the shark swam into a smooth patch of water near our boat, it became clear it was a white shark!'
A second great white then approached and started swimming in circles with the other shark at the surface as everyone on the boat looked on in awe, according to 7 Seas.
See photos of the sharks:
'We have only seen this species a handful of times in the 42 years we have been in business,' the post stated.
There have been several other recent sightings of sharks off Cape Cod and Nantucket as well, according to the Chatham-based Atlantic White Shark Conservancy's Sharktivity app.
The Sharktivity app, which is available to download on iPhone and Android, tracks sightings fed by researchers, safety officials, and users who upload photos for confirmation.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
9 hours ago
- Business Insider
Cofounder of Neuralink rival Precision Neuroscience reveals what people often get wrong about brain implants
At least that's the line from Dr. Ben Rapoport, the cofounder and chief science officer of Precision Neuroscience, a brain-computer interface, or BCI, company. "Many people have the impression that the data that we care about is sort of everywhere inside this dimensional structure," Rapoport, a neurosurgeon and engineer, told Business Insider. That's a big misconception, he said. People often incorrectly assume that "you need electrodes that penetrate deep inside the brain to get that information out," he added. But brain implants don't need to be as invasive as they might sound, he said. Precision is developing a thin film that sits on the brain and records brain activity in patients with paralysis. "We implant modules of 1,024 electrodes on the brain surface in the area that controls movement, especially the hand," Rapoport said. That allows them to have cursor control, typing ability, access the internet, use PowerPoint, play games, and word process, he added. These are actions that require vision, movement, sensation, and executive function — core parts of consciousness that are concentrated in the brain's outermost layer, the cortex, Rapoport said. Deeper inside are "connections, you know, between those activities and also sort of subconscious processes, because the brain coordinates a lot of activities in the body that don't take place consciously," he added. The New York-based startup, which received FDA clearance for part of its wireless brain-computer interface in April, has raised $155 million in funding since it launched in 2021. It is one of a few companies advancing this technology as part of the Implantable BCI Collaborative Community. BCIs are largely classified into two categories: invasive and non-invasive. Non-invasive BCIs, which don't require surgery, often rely on external sensors to detect the electrical signals in the brain. BCS that are implanted record neural activity directly from the brain and are being developed to restore speech, movement, and other complex functions in people with neurological conditions. The buzziest BCI these days is Elon Musk's Neuralink, which has ambitions to create a "symbiosis" between the human brain and AI. But there are a host of other companies working on BCIs as a way to treat neurological diseases, like Precision Neuroscience. The company has tested its temporary device in over forty patients in early clinical studies. Over the next year, it will prepare for the first human studies of its permanently implanted devices. "There are certain internal validation checks and internal milestones that we need to meet for ourselves and for the FDA before we want to start implanting the permanently implanted wireless device in humans," Rapoport said. The company's ultimate goal is to help paralyzed people get "back to a level of functional capacity where they can be significantly independent, economically self-sufficient, and hold a job in the workplace," Rapoport said. Correction: June 27, 2025 — An earlier version of this story said that Dr. Ben Rapoport was the founder and CEO of Precision Neuroscience; Dr. Rapoport is the cofounder and chief science officer. An earlier version also mischaracterized the film that goes on the brain. It is not studded with electrodes; the electrodes are embedded.
Yahoo
16 hours ago
- Yahoo
AI in drug discovery: from hypothetical to reality
AI has been a buzzword in the pharmaceutical industry for almost a decade, with countless headlines promising to revolutionise how drugs are discovered, developed, and deployed. The hype has typically outpaced reality; however, with a growing number of AI-generated drug candidates entering clinical trials, we find ourselves at a crucial potential turning point for the field. As the first AI-designed molecules begin clinical trials, the industry is watching closely to see if AI can deliver novel, successful therapies or if it will remain a supporting tool in an already complex research process. AI is not a single technology, but a broad set of computational tools that can support nearly every stage of drug development. In early discovery, AI can help identify novel targets, generate new chemical compounds, predict how drugs will interact with proteins, and optimise lead compounds (promising compounds that show potential as an effective drug) for desirable properties. In later stages, it is increasingly used to select patients for clinical trials, repurpose existing drugs, and predict adverse effects. Early attention focused on the ability of generative AI models, particularly deep learning and reinforcement learning frameworks, to create candidate compounds faster than any human chemist, with a theoretical ability to explore vast chemical spaces more efficiently than traditional methods. AI-designed candidates used to remain confined to in silico (computational) experiments or the preclinical stage. That is now changing. In the past two years, several AI-designed drugs have advanced into human trials, providing the first real-world test of these technologies in the clinic. Insilico Medicine, a Hong Kong- and New York-based AI biotech company, gained attention in 2023 when it announced that its drug candidate INS018_055, developed using its proprietary platform, had entered Phase II trials (testing effectiveness and safety). The compound was designed from scratch using generative models trained on structural data, an early confirmation that AI can do more than just screen libraries. Other companies such as BenevolentAI, Recursion, Schrödinger, and Relay Therapeutics are advancing candidates identified, optimised, or prioritised using AI tools, though not all are strictly 'AI-generated'. Importantly, these companies are not just discovering molecules but also positioning themselves as drug developers and strategic collaborators. Big pharma has increasingly embraced AI, using partnerships, joint ventures, and acquisitions to reduce risk in target selection and accelerate early-stage drug development. A prime example is this deal between Sanofi and Exscientia, worth up to $5.2bn, focused on AI-designed small molecules across oncology and immunology. Furthermore, AstraZeneca has been collaborating with BenevolentAI to identify new drug targets in chronic kidney disease and fibrosis. Pfizer, Bayer, Merck, and Roche have all partnered with AI-native biotechs or built their own internal capabilities, often focused on areas such as rare diseases, central nervous system disorders, or target deconvolution. These collaborations reflect a broader shift in mindset: AI is increasingly seen not as a competitor to traditional research and development (R&D), but as a strategic enabler, using human expertise to improve accuracy and compress timelines in high-risk areas. The core value proposition of AI in drug discovery is speed and efficiency. Drug development typically costs over $2bn and can take 10-15 years per new drug. AI promises to shorten the time from target identification to candidate nomination by rapidly generating hit compounds, improving target-disease linkage accuracy, and selecting better patient populations for trials. Insilico, for example, claimed that INS018_055 progressed from target discovery to Investigational New Drug filing in under 30 months, significantly faster than industry averages. However, real-world validation of these efficiency claims is still pending, and it remains unclear whether AI shortens timelines in later-stage development, where most costs and failures still occur. Moreover, regulatory pathways for AI-designed drugs are still evolving. While the molecules themselves follow industry standards, questions remain around intellectual property ownership, algorithm transparency, and validation of model-generated hypotheses. The excitement around AI in drug discovery has driven enormous investor interest, bringing volatility along with it. Many AI-first biotech companies raised substantial capital through initial public offerings or special-purpose acquisition companies (SPACs) deals during the 2021-22 biotech boom. Yet several have seen share prices decline sharply as investor enthusiasm met the realities of long development timelines, modest clinical progress, and uncertain monetisation strategies. BenevolentAI, for example, went public via a €1.5bn ($1.8bn) SPAC in 2022 but lost over 70% of its value by mid-2024. Recursion, despite its ambitious data-driven drug discovery platform and partnerships with Bayer and Roche, has also faced pressure from shareholders seeking faster returns. Despite this, the field is still maturing. Investors and pharma partners are shifting from broad platforms to more focused evaluations based on data-driven productivity, clinical progress, and pipeline value. The industry is now approaching a key milestone: the first regulatory approval of an AI-designed drug. If INS018_055 delivers positive Phase II data, it would mark a transformative moment, validating AI not just as a tool but as a source of new and unique therapies. Looking further ahead, AI could diversify drug development by enabling smaller companies to design high-quality molecules without vast lab infrastructure. It may also unlock progress in rare diseases, neglected indications, or emerging pathogens, where traditional business models struggle to justify investment. Beyond small molecules, AI is also being explored in biologics design, protein engineering, messenger ribonucleic acid optimisation, and clinical trial design, suggesting its impact could extend across the entire pharmaceutical value chain. AI is no longer just a futuristic concept in pharma; it is producing real assets, forming strategic alliances, and slowly earning its place in the clinical pipeline. However, expectations remain high, and the burden of proof now rests on human trials, not machine models. As the first wave of AI-designed drugs enters mid-stage development, the industry will be watching not just for approvals, but for evidence that AI can improve outcomes, accelerate timelines, and reduce costs in a field where failure is still the norm. If successful, the next decade may not just belong to AI, it may be designed by it. "AI in drug discovery: from hypothetical to reality" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
New York Post
17 hours ago
- New York Post
Explore the universe with this Smart Telescope, now $270!
Discover startups, services, products and more from our partner StackCommerce. New York Post edits this content, and may be compensated and/or receive an affiliate commission if you buy through our links. TL;DR: View the universe anytime, anywhere with the first-ever Smartphone-based Telescope, now on sale for $259.99 (reg. $299.99) with free shipping. Many substitute the city's dazzling lights for the beauty of the galaxy. While that's cool and all, let's be real—nothing quite beats a blanket of stars and constellations, but the MTA can only get you so far away from the city. Fortunately, we have the perfect solution for you. Meet the Hestia Smartphone-based Telescope, which allows you to explore the universe day or night. Now you can snag one for $259.99 (reg. $299.99) and get free shipping! So, what is a Smartphone-based Telescope? The Hestia is designed to attach to iPhones (iOS 16.0 or later) and Android devices (Android 11 or later) to amplify the main camera through the Vanois Gravity app. It's built with six different lenses, making images up to 5x sharper with a magnification of 25x. With that kind of close-up, you can live out your childhood dream of being an astronaut, without ever leaving the ground! By hopping on this deal, not only do you save a few bucks, but you get everything you need to explore space by day or night. The Ultimate Pack comes equipped with Hestia's premium tripod, a high-quality solar filter, a precision solar pointer, a transportation case, and a visor. All you're missing is a snack and bev. Better yet, this telescope is built to last. It relies solely on an optical design system, aka your phone, so there's no need for battery or risk of power loss. Plus, it's waterproof, temperature resistant, and impact resistant, so you don't have to worry about someone bumping into you. Trek out to Central Park, where the trees and skyscrapers can't disrupt your view, pick your destination on the Gravity app, and enjoy the vast wonders of space. Choose between three different modes: Day, Night, or Scenery Mode to learn more about the Sun, Moon, and catalogue your surroundings up close in crystal-clear quality. Who knows, you may find a new planet with this baby. Fuel your inner child and grab Hestia's first-ever Smartphone-based Telescope (Ultimate Pack) for only $259.99 (reg. $299.99) with free shipping. StackSocial prices subject to change.
